The complaint alleges that ADMA Biologics violated the Securities Exchange Act of 1934 by disseminating false and misleading information. Specifically, the suit highlights the use of channel stuffing to fabricate revenue growth and a failure to maintain necessary internal controls. These actions allegedly obscured the company's true financial standing until the discrepancies surfaced, causing significant losses for shareholders.
Brian Schall of the Los Angeles-based firm is inviting affected investors to discuss their legal standing before the August 10, 2026, deadline. As the class has not yet been certified, shareholders currently remain absent class members and must take active steps to participate in the recovery effort. Those interested in the case can reach the firm at 310-301-3335 or via their official website.
Comments (0)
No comments yet. Be the first!